Table 3.

Concurrent therapy and prognostic factors

	MGMT (methylated, not methylated)	IDH (mutated, not mutated)	Age (years) (59 or less, > 60)	KPS (90 or 100, 70 or 80)
No vaccine (n = 3)	1 vs 2	0 vs 3	1 vs 2	2 vs 1
2 or 3 vaccinations, no concurrent therapy (n = 8)	3 vs 5	1 vs 7	4 vs 4	1 vs 7
Concurrent TMZ alone (n = 29)	8 vs 21	4 vs 25	18 vs 11	17 vs 12
Concurrent TMZ + bevacizumab (n = 11)	3 vs 8	2 vs 9	7 vs 4	6 vs 5
Concurrent TMZ + TTF (n = 6)	3 vs 3	0 vs 6	2 vs 4	3 vs 3
Concurrent TMZ + TTF + bevacizumab (n = 3)	1 vs 2	0 vs 3	1 vs 2	2 vs 1
Total (n = 60)	19 vs 41	7 vs 53	33 vs 27	31 vs 29

IDH isocytrate dehydrogenase, MGMT O-6-methylguanine-DNA methyltransferase, TMZ temozolomide, TTF tumor treating fields;